CIRCULATING TUMOR DNA (LIQUID BIOPSY)

Circulating tumor DNA as a liquid biopsy for cancer.

BACKGROUND Targeted therapies have markedly changed the treatment of cancer over the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a result of tumor heterogeneity, clonal evolution, and selection. Although genotyping is the most currently used method for categorizing tumors for clinical decisions, tumor tissues provide only a snapshot, or are often diffic...

Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)

Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)

©2017 Blue Cross and Blue Shield of Louisiana An independent licensee of the Blue Cross and Blue Shield Association No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana. Page 1 of 14 Applies to all products admin...

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.

UNLABELLED "Liquid biopsy" focusing on the analysis of circulating tumor cells (CTC) and circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received enormous attention because of its obvious clinical implications for personalized medicine. Analyses of CTCs and ctDNA have paved new diagnostic avenues and are, to date, the cornerstones of liquid biopsy diagnostics. T...

Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)